Objective: Sporadic, genetically complex essential tremor (ET) is one of the most common movement disorders and may lead to severe impairment of the quality of life. Despite high heritability, the genetic determinants of ET are largely unknown. We performed the second genome-wide association study (GWAS) for ET to elucidate genetic risk factors of ET.
dizygotic twins. 4 The pathogenesis of ET is largely unknown. Two competing hypothesis based on neurophysiologic, pathologic, and animal data state that ET could either be a neurofunctional disorder caused by abnormal oscillations possibly generated in the inferior olivary nucleus or a neurodegenerative disorder of the cerebellum. 5 However, it can also not be excluded that both hypotheses apply, e.g., that permanent longstanding abnormal oscillations transmitted to the cerebellum ultimately lead to neurodegeneration. The first genome-wide association study (GWAS) for ET identified an association between a variant in the LINGO1 gene and ET in a first-stage sample composed of Icelandic patients. 6 This finding was confirmed by several but not all other groups attempting replication. [7] [8] [9] Here, we present the second GWAS for ET.
METHODS Standard protocol approvals, registrations, and patient consents. The local ethics committees approved the study. Written informed consent was obtained from all participants. Study samples. ET was diagnosed according to the TRIG criteria. 1 In the first stage we analyzed 436 patients and 928 control subjects of German origin. The second-stage independently collected verification sample consisted of 554 patients and 609 control subjects of European (Germany, Denmark, and Austria) origin. Control samples were of German, Austrian, and Danish origin. Recent publications only found minor genetic differences between Germans, Austrians, and Danes. 10, 11 Therefore, we combined the samples from these 3 different populations in stage 2. In this study we analyzed only patients with definite or probable ET but not possible ET, which is the weakest diagnostic category according to the TRIG criteria, to achieve maximal diagnostic certainty. All control subjects were screened negative for ET by a validated screening procedure. 12 Control subjects were not matched to patients regarding the sex ratio, and no adjustment for gender was performed because no sexspecific differences in epidemiologic data, pathogenesis, or clinical presentation are known. The 847 German patients from Kiel used in stages 1 and 2 were recruited by movement disorder specialists at the Department of Neurology of the University Hospital of Schleswig-Holstein, campus Kiel, and also in cooperation with the PopGen Biobank. 13 The 928 German control subjects for the genome-wide scan were obtained from the Pop-Gen Biobank. 13 For the second-stage analyses, 75 healthy German spouses were recruited as control subjects at the University Hospital of Schleswig-Holstein, Kiel campus, and 478 German control subjects were recruited from the Kiel aging project within PopGen. 14 The recruitment of the Danish patient and control sample (stage 2) has been described elsewhere. 4 German patients with ET from Tübingen (stage 2) were recruited from the movement disorder clinic at the Center of Neurology, University of Tübingen. Patients were systematically examined, and ET was diagnosed by movement disorder specialists. After the initial diagnosis, patients were followed for at least 5 years to All demographic data refer to study samples before genotyping quality control was applied.
exclude diagnoses other than definite ET. Patients showing clinical signs or imaging abnormalities not compatible with a diagnosis of ET, such as progressive cerebellar dysfunction, parkinsonism, dystonia, or MRI abnormalities, were excluded. A total of 64 Austrian patients were recruited by movement disorder specialists from the movement disorder clinic at the Department of Neurology, Innsbruck Medical University.
Genotyping and quality control. Samples with Ͼ10%
missing genotypes in the single nucleotide polymorphism (SNP) sets analyzed were excluded in all analyses in the first and second stage and in the LINGO1 analysis. The first-stage genotyping of this study was performed using the Affymetrix Genome-Wide SNP Array 6.0 (1000K) (Affymetrix, Santa Clara, CA). Affymetrix processed more than 99% of the samples. Genotypes were called using the Affymetrix Birdseed v2 algorithm. We used visual inspection of cluster plots to exclude false-positive associations among the highest ranking SNPs typed in the first stage. As part of the comprehensive quality control (QC) of the first stage, only markers with a call rate Ն95% in patients and control subjects, with a minor allele frequency (MAF) Ն0.05 in control subjects, and with p Ͼ 0.0001 for Hardy-Weinberg equilibrium were considered for association analysis. We investigated the first-stage sample for population stratification as well as for identical or related individuals based on pairwise identity-by-state distance and calculated the genomic inflation factor with the use of PLINK (version 1.04; http://pngu.mgh.harvard.edu/ϳpurcell/plink/) and of R (version 2.10.0; http://www.r-project.org/). 15, 16 Quantile-quantile plots were created using the qq.chisq function of the R package snpMatrix (version 1.0.33, http://www-gene.cimr.cam.ac.uk/clayton/software/). 17 Genotyping of samples for the second verification step and subsequent fine mapping was performed with SNPlex (Applied Biosystems, Foster City, CA), MassARRAY iPLEX platform (Sequenom Inc, San Diego, CA) and TaqMan technology (Applied Biosystems) following standard protocols. QC criteria for second-stage genotyping were minimal genotype call rate Ͼ95% for each SNP, MAF Ն0.05, and p Ͼ 0.01 for Hardy-Weinberg equilibrium. Multiple testing correction for the second-stage SNPs was performed using the mperm 1000 permutation command of PLINK. SNPs for subsequent fine mapping were selected from the European HapMap CEU reference data (http://hapmap.org/).
Statistical analysis.
All association analyses were performed using R (version 2.10.0) 16 and PLINK (version 1.04). 15 Genotype-phenotype associations were assessed for statistical significance using a 2 test. In addition to the comparison of the allelic frequencies of patients and control subjects, association was also calculated using genotype frequencies as well as recessive and dominant genetic models. The different models did not differ significantly from the allelic model, and therefore these models were disregarded.
RESULTS
To identify additional ET susceptibility loci, we performed a two-stage GWAS. The demographical data for all samples are found in table 1.
The first-stage sample had 80% power to detect a disease-associated variant with an odds ratio (OR) of Ն1.6 at the 5% significance level, assuming a MAF of Ն0.1 in healthy control subjects (figure e-1 on the Neurology Web site at www.neurology.org). After extensive QC, 620,077 SNPs were tested in the exploratory first stage. The estimated genomic inflation factor of ϭ 1.077 indicated very low population substructure in the sample, obviating the need for correction. In the first stage, no marker reached genome-wide significance ( p Յ 8 ϫ 10 Ϫ8 ). An overview of the GWAS p values in form of a Manhattan plot is given in figure e-2. The quantile-quantile plot (figure e-3) showed only a slight excess of signal. Visual inspection of the cluster plots of all 535 SNPs with p Ͻ 10 Ϫ4 led to removal of 462 SNPs with bad genotyping quality. The first-stage association results for all SNPs p Ͻ 10 Ϫ4 ,which passed the visual inspection of the cluster plots, are shown in table e-1. All remaining SNPs with p Ͻ 10 Ϫ5 (n ϭ 17) as well as SNPs with p Ͻ 10 Ϫ4 (n ϭ 9), which showed support of at least 1 additional correlated SNP with p Ͻ 10 Ϫ4 and 4 SNPs located in functional candidate genes (SLC1A2, GARB1, KCNU1, and SMOC2) with p Ͻ 10 Ϫ4 were selected for second-stage genotyping in an independent verification sample of 554 patients and 609 control subjects of European origin. Four SNPs were excluded from the analysis because of insufficient genotyping quality, leaving 26 SNPs for the second-stage analysis (table e-2). Two SNPs showed nominally significant p values. Only one of these variants (rs3794087), located in intron 4 of the SLC1A2 gene (OMIM 600300) on chromosome 11p13, passed the correction for multiple testing and reached a corrected allelic p ϭ 0.037 in the secondstage sample (table e-2). SNP rs3794087 yielded a nominal p ϭ 1.16 ϫ 10 Ϫ7 in the combined first-and second-stage sample (table 2). In the subgroup analysis of the most stringent phenotype of definite ET (n ϭ 658), the SNP rs3794087 achieved a genomewide significant p ϭ 3.44 ϫ 10 Ϫ10 in the combined sample (table 2) . The sample sizes are too small for a meaningful further subgroup analyses (e.g., patients with a positive family history or patients with a positive alcohol response).
For fine mapping, we tested 7 SNPs in high linkage disequilibrium with rs3794087 (r 2 Ͼ 0.8) and in addition 8 nonsynonymous coding SNPs located in the SLC2A1 gene (figure 1). Seven of these 15 SNPs tested for fine mapping were monomorphic in the study population. None of the remaining 8 SNPs showed a stronger association with ET than rs3794087. The genetic region of the SLC1A2 gene is characterized by a weak linkage disequilibrium structure (figure 1).
We also investigated 3 published LINGO1 SNPs. 6, 8 These SNPs were not included on the Affymetrix SNP Array 6.0, and no other SNP in the region of LINGO1 present on the array showed a significant association in the first GWAS stage. We were just able to replicate the association of the LINGO1 SNP rs9652490 with ET in the combined sample of the first and second stage with p ϭ 0.0135 and OR ϭ 1.20. The other 2 SNPs (rs8030859 and rs11856808) showed no significant association (data not shown). Recently, we replicated the association of variants in the LINGO1 gene in a German sample of ET patients, which partly shared subjects with the first and second samples used in this GWAS. 8
DISCUSSION
The present GWAS revealed an association between the SNP rs3794087 in intron 4 of the SLC1A2 gene and ET. The estimated OR of ϳ1.5 is in the typical range of ORs found in GWAS. However, it should be kept in mind that it does not allow any risk prediction on an individual patient basis. The function of this noncoding SNP is unknown. Independent replication studies are needed, especially because rs3794087 did not achieve genome-wide significance in the first-stage analysis. However, it is interesting to note that the association of rs3794087 was consistently stronger if only patients with the highest diagnostic certainty (definite ET) were included in the analysis and reached genome-wide significance in the smaller subgroup of 658 patients with definite ET after genotyping QC in the combined first-and second-stage samples. The SLC1A2 gene encodes the predominant glutamate reuptake transporter (excitatory amino acid transporter 2), which removes glutamate from the synaptic cleft. Glutamate is the major excitatory neurotransmitter in the CNS. Prolonged elevated glutamate concentrations in the synaptic cleft are neurotoxic (so-called "excitotoxicity") and thought to contribute to neurodegenerative disorders such as Alzheimer disease and amyotrophic lateral sclerosis. Based on the acute harmaline animal model of ET, a widely recognized hypothesis assumes that the abnormal oscillations causing the tremor are generated in the inferior olive and transmitted through the cerebellum to other brain areas. 18 The inferior olivary neurons but not the cerebellar Purkinje neurons that are involved contain abundant NMDA-type glutamate receptors. 19 Harmalineinduced tremor is blocked by NMDA receptor antagonists, suggesting that NMDA receptor activation is necessary to generate the abnormal olivary oscillation. 20 In addition, sustained glutamatergic excitation of climbing fiber terminals in the cerebellum might be toxic to Purkinje neurons. 19 Interestingly, SLC1A2 is strongly expressed in the inferior olive but not in other structures of the brain stem. 21 Ethanol, which acutely alleviates ET in many patients significantly increases SLC1A2 expression and glutamate uptake activity. 22 Furthermore, elevated glutamate concentrations are present in the CSF and serum of patients with ET. 23 For further progress in the genetics of sporadic ET, 2 prerequisites have to be met. First, sample sizes have to be increased, either in subsequent studies or by pooling data of current and future studies. Second, detailed clinical assessment using the same diagnostic criteria in all studies as well as the assessment of intermediary phenotypes, first and foremost alcohol responsiveness, might lead to genetically more homogeneous ET samples. A standardized test to assess alcohol responsiveness is currently under development in our group. In conclusion, this is the first report showing an association of the glutamatergic amino acid transporter SLC1A2 and ET.
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